Sanhong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sanhong Liu has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Dong Zhang
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao‐di Herbs Institute of Medicinal Plant Development Chinese Academy of Medical Sciences & Peking Union Medical College Beijing China
17 shared publications Dianping Yu
16 shared publicationsMengting Xu
15 shared publicationsQing Zhang
15 shared publicationsHongmei Hu
14 shared publicationsLinyang Li
12 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Elsevier in Cell Reports Medicine
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity
- 19 October 2026
- Published by Elsevier in Cell Reports Medicine
Open AccessIsobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity
- Open Access
- 15 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (20)
Expression of Concern for Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1
- 15 October 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (20)
Open AccessExpression of Concern for Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1
- Open Access
- 13 July 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102920
Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination
- 13 July 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (7) , 102920
Open AccessRepurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination
- 21 March 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (3) , 189579
Targeting BATF: A new strategy for cancer immunotherapy
- 21 March 2026
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1881 (3) , 189579
Targeting BATF: A new strategy for cancer immunotherapy
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8237-8254
Chemical Space Navigation of Nitidine Leads to the Discovery of a Novel PD-L1 Degradation Agent by Targeting CSN5 for Enhanced Antitumor Immunity
Expanding the chemical space of natural products is an effective strategy for discovering new drug candidates and has achieved remarkable results in activity screening. To efficiently explore the chemical space of nitidine, we developed a one-pot method to synthesize functionalized phenanthridines using commercially available or easily prepared aldehydes. Assisted by pyrrolidine and photocatalysts, the reaction proceeded under visible light at room temperature with satisfactory yields. Activity screening identified derivative e24, which reduced tumor cell PD-L1 expression more effectively than positive control JQ-1, while the prototype nitidine had minimal effects. Critically, e24 specifically targets CSN5, an essential regulatory factor, to induce PD-L1 degradation, thereby blocking the PD-1/PD-L1 interaction between T cells and tumor cells and activating the tumor immune microenvironment. In Lewis tumor and MC38 mice models, e24 exerted antitumor effects by enhancing tumor-infiltrating T-cell immunity and inhibiting the activation of immunosuppressive MDSCs and Tregs.
- 13 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (7) , 8237-8254
Chemical Space Navigation of Nitidine Leads to the Discovery of a Novel PD-L1 Degradation Agent by Targeting CSN5 for Enhanced Antitumor Immunity
Expanding the chemical space of natural products is an effective strategy for discovering new drug candidates and has achieved remarkable results in activity screening. To efficiently explore the chemical space of nitidine, we developed a one-pot method to synthesize functionalized phenanthridines using commercially available or easily prepared aldehydes. Assisted by pyrrolidine and photocatalysts, the reaction proceeded under visible light at room temperature with satisfactory yields. Activity screening identified derivative e24, which reduced tumor cell PD-L1 expression more effectively than positive control JQ-1, while the prototype nitidine had minimal effects. Critically, e24 specifically targets CSN5, an essential regulatory factor, to induce PD-L1 degradation, thereby blocking the PD-1/PD-L1 interaction between T cells and tumor cells and activating the tumor immune microenvironment. In Lewis tumor and MC38 mice models, e24 exerted antitumor effects by enhancing tumor-infiltrating T-cell immunity and inhibiting the activation of immunosuppressive MDSCs and Tregs.
- Open Access
- 27 January 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Paroxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation
Background: Immunotherapy targeting the PD-1/PD-L1 axis shows promise in colon and lung cancer treatment but faces challenges like high costs, low response rates, and drug resistance. Developing new small molecule inhibitors is complex. Repurposing existing drugs offers advantages, and paroxetine (PAR), an FDA approved antidepressant, has shown potential antitumor effects, yet its role as an immune checkpoint inhibitor is unclear. Methods: In this study, we investigated PAR as an immune checkpoint inhibitor. We used various cell lines, including colon and lung cancer cells, and in vivo mouse models. Techniques such as Western blotting, flow cytometry, immunofluorescence, and immunohistochemistry were employed to analyze protein expression, cell surface marker levels, and immune cell populations. We also conducted gene knockdown and overexpression experiments, as well as molecular docking and binding assays. Results: PAR downregulates PD-L1 protein levels in a concentration and time dependent manner in multiple cancer cell lines. In vivo, it inhibits tumor growth in colon and lung cancer mouse models by activating T cell immunity. Mechanistically, PAR binds to the Asp130 site of speckle-type POZ protein (SPOP), stabilizing this E3 ubiquitin ligase to promote PD-L1 ubiquitination and proteasomal degradation. Moreover, PAR combines with an anti-CTLA4 antibody enhances cancer cell inhibition, and it also suppresses AOM/DSS induced colon cancer. Conclusions: Our findings demonstrate that PAR can function as an immune checkpoint inhibitor by targeting SPOP to degrade PD-L1, enhancing antitumor immunity. This provides a new theoretical basis for using PAR in colorectal and lung cancer treatment and offers insights into repurposing other drugs for cancer therapy.
- 27 January 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessParoxetine repurposing enhances antitumor immunity via SPOP-mediated PD-L1 ubiquitination and proteasomal degradation
Background: Immunotherapy targeting the PD-1/PD-L1 axis shows promise in colon and lung cancer treatment but faces challenges like high costs, low response rates, and drug resistance. Developing new small molecule inhibitors is complex. Repurposing existing drugs offers advantages, and paroxetine (PAR), an FDA approved antidepressant, has shown potential antitumor effects, yet its role as an immune checkpoint inhibitor is unclear. Methods: In this study, we investigated PAR as an immune checkpoint inhibitor. We used various cell lines, including colon and lung cancer cells, and in vivo mouse models. Techniques such as Western blotting, flow cytometry, immunofluorescence, and immunohistochemistry were employed to analyze protein expression, cell surface marker levels, and immune cell populations. We also conducted gene knockdown and overexpression experiments, as well as molecular docking and binding assays. Results: PAR downregulates PD-L1 protein levels in a concentration and time dependent manner in multiple cancer cell lines. In vivo, it inhibits tumor growth in colon and lung cancer mouse models by activating T cell immunity. Mechanistically, PAR binds to the Asp130 site of speckle-type POZ protein (SPOP), stabilizing this E3 ubiquitin ligase to promote PD-L1 ubiquitination and proteasomal degradation. Moreover, PAR combines with an anti-CTLA4 antibody enhances cancer cell inhibition, and it also suppresses AOM/DSS induced colon cancer. Conclusions: Our findings demonstrate that PAR can function as an immune checkpoint inhibitor by targeting SPOP to degrade PD-L1, enhancing antitumor immunity. This provides a new theoretical basis for using PAR in colorectal and lung cancer treatment and offers insights into repurposing other drugs for cancer therapy.
- Open Access
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1
Programmed cell death 1 ligand 1–targeted (PD-L1–targeted) immune checkpoint inhibitors are revolutionizing cancer therapy. However, strategies to induce endogenous PD-L1 degradation represent an emerging therapeutic paradigm. Here, we identified proanthocyanidins (PC) as a potent inducer of PD-L1 degradation through an endoplasmic reticulum–associated degradation (ERAD) mechanism. Mechanistically, PC exerted dual effects: First, it targeted and stabilized LKB1 to activate AMPK in tumor cells, subsequently inducing the phosphorylation of PD-L1 at Ser195 — a disruption that in turn impaired glycosylation of PD-L1 and promoted its retention in the ER. Second, PC directly bound to the E3 ubiquitin ligase SYVN1 to increase its protein stability, which strengthened PD-L1–SYVN1 binding, thereby accelerating K48-linked ubiquitination and proteasomal degradation of ER-retained PD-L1. This cascade culminated in the activation of CD8 + T cell–dominated antitumor immune responses, accompanied by suppression of myeloid-derived suppressor cells and regulatory T cells. In preclinical models of lung and colorectal cancer, PC exhibited synergistic antitumor efficacy when combined with anti–cytotoxic T lymphocyte antigen 4 (anti–CTLA-4) antibodies. Notably, PC also potently inhibited the progression of azoxymethane/dextran sodium sulfate–induced orthotopic colorectal cancer in mice. Collectively, our findings unveil an antitumor mechanism of PC, establishing this small-molecule compound as an ERAD pathway–exploiting immune checkpoint modulator with promising translational potential for cancer therapy.
- 2 December 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (3)
Open AccessProanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1
Programmed cell death 1 ligand 1–targeted (PD-L1–targeted) immune checkpoint inhibitors are revolutionizing cancer therapy. However, strategies to induce endogenous PD-L1 degradation represent an emerging therapeutic paradigm. Here, we identified proanthocyanidins (PC) as a potent inducer of PD-L1 degradation through an endoplasmic reticulum–associated degradation (ERAD) mechanism. Mechanistically, PC exerted dual effects: First, it targeted and stabilized LKB1 to activate AMPK in tumor cells, subsequently inducing the phosphorylation of PD-L1 at Ser195 — a disruption that in turn impaired glycosylation of PD-L1 and promoted its retention in the ER. Second, PC directly bound to the E3 ubiquitin ligase SYVN1 to increase its protein stability, which strengthened PD-L1–SYVN1 binding, thereby accelerating K48-linked ubiquitination and proteasomal degradation of ER-retained PD-L1. This cascade culminated in the activation of CD8 + T cell–dominated antitumor immune responses, accompanied by suppression of myeloid-derived suppressor cells and regulatory T cells. In preclinical models of lung and colorectal cancer, PC exhibited synergistic antitumor efficacy when combined with anti–cytotoxic T lymphocyte antigen 4 (anti–CTLA-4) antibodies. Notably, PC also potently inhibited the progression of azoxymethane/dextran sodium sulfate–induced orthotopic colorectal cancer in mice. Collectively, our findings unveil an antitumor mechanism of PC, establishing this small-molecule compound as an ERAD pathway–exploiting immune checkpoint modulator with promising translational potential for cancer therapy.
- Open Access
Cordycepin Targets HRD1 to Promote Cancer Cell PD‐L1 Ubiquitin–Proteasome Degradation and Increase Antitumor Immunity
Immune checkpoint blockade has become an effective strategy for inhibiting tumor growth, especially immune checkpoint inhibitors that target the programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) pathway, which have shown significant effects in tumor immunotherapy. In this study, we found that naturally sourced Cordyceps militaris extract can effectively downregulate the protein expression level of PD‐L1 in human colorectal cancer cell lines. Further systematic isolation, purification, and analysis of its active components revealed that cordycepin (COR) is the key active molecule mediating PD‐L1 degradation. Mechanistically, COR specifically and selectively targets the ubiquitin E3 ligase HMG‐CoA reductase degradation protein 1, thus promoting the degradation of PD‐L1 protein through the ubiquitin–proteasome pathway. This process significantly enhances the cytotoxic killing effect of effector T lymphocytes against colorectal cancer cells, ultimately achieving robust antitumor effects. Furthermore, this study also revealed that COR exhibits potential synergistic therapeutic effects when combined with anti‐CTLA4 antibodies in preclinical tumor treatment. In summary, COR, as the primary bioactive component of Cordyceps militaris , demonstrates considerable potential to act as a small‐molecule immune checkpoint modulator and inhibitor, thereby providing a novel therapeutic strategy for the immunotherapy of colorectal cancer.
Open AccessCordycepin Targets HRD1 to Promote Cancer Cell PD‐L1 Ubiquitin–Proteasome Degradation and Increase Antitumor Immunity
Immune checkpoint blockade has become an effective strategy for inhibiting tumor growth, especially immune checkpoint inhibitors that target the programmed death 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) pathway, which have shown significant effects in tumor immunotherapy. In this study, we found that naturally sourced Cordyceps militaris extract can effectively downregulate the protein expression level of PD‐L1 in human colorectal cancer cell lines. Further systematic isolation, purification, and analysis of its active components revealed that cordycepin (COR) is the key active molecule mediating PD‐L1 degradation. Mechanistically, COR specifically and selectively targets the ubiquitin E3 ligase HMG‐CoA reductase degradation protein 1, thus promoting the degradation of PD‐L1 protein through the ubiquitin–proteasome pathway. This process significantly enhances the cytotoxic killing effect of effector T lymphocytes against colorectal cancer cells, ultimately achieving robust antitumor effects. Furthermore, this study also revealed that COR exhibits potential synergistic therapeutic effects when combined with anti‐CTLA4 antibodies in preclinical tumor treatment. In summary, COR, as the primary bioactive component of Cordyceps militaris , demonstrates considerable potential to act as a small‐molecule immune checkpoint modulator and inhibitor, thereby providing a novel therapeutic strategy for the immunotherapy of colorectal cancer.
- Open Access
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (41) , 37089-37103
Marine Natural Product Chagosendine C Induces Cuproptosis in Colorectal Cancer Cells by Targeting FDX1
Colorectal cancer (CRC) treatment is hampered by high recurrence rates and drug resistance. Cuproptosis, a copper-induced cell death mechanism, offers a new therapeutic approach. Here, we identified a marine natural product, chagosendine C (CHC), which kills tumor cells by increasing the intracellular copper ion concentration. CHC and related metal coordination homodimer alkaloids were rapidly synthesized and purified for further pharmacological study. In vitro, CHC significantly inhibited HCT116 and RKO CRC cell growth, induced G1 phase arrest and cell death, and overcame oxaliplatin resistance. In vivo, CHC suppressed colorectal tumor growth in mice at 40 mg/kg without obvious toxic effects. Mechanistically, CHC induces cuproptosis by targeting FDX1, increasing intracellular copper ions and ROS levels in tumor cells, and leading to cell death. Thus, CHC presents a novel CRC treatment strategy, showing strong antitumor activity and potential to overcome oxaliplatin resistance with promising clinical prospects.
- 22 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (41) , 37089-37103
Open AccessMarine Natural Product Chagosendine C Induces Cuproptosis in Colorectal Cancer Cells by Targeting FDX1
Colorectal cancer (CRC) treatment is hampered by high recurrence rates and drug resistance. Cuproptosis, a copper-induced cell death mechanism, offers a new therapeutic approach. Here, we identified a marine natural product, chagosendine C (CHC), which kills tumor cells by increasing the intracellular copper ion concentration. CHC and related metal coordination homodimer alkaloids were rapidly synthesized and purified for further pharmacological study. In vitro, CHC significantly inhibited HCT116 and RKO CRC cell growth, induced G1 phase arrest and cell death, and overcame oxaliplatin resistance. In vivo, CHC suppressed colorectal tumor growth in mice at 40 mg/kg without obvious toxic effects. Mechanistically, CHC induces cuproptosis by targeting FDX1, increasing intracellular copper ions and ROS levels in tumor cells, and leading to cell death. Thus, CHC presents a novel CRC treatment strategy, showing strong antitumor activity and potential to overcome oxaliplatin resistance with promising clinical prospects.
- Open Access
- 22 August 2025
- Published by Elsevier in Engineering
- Vol. 54, 261-276
Icaritin Improves the Hematopoiesis-Supportive Function of MSCs via A PRDX1–MAPK Axis After Chemotherapy
- 22 August 2025
- Published by Elsevier in Engineering
- Vol. 54, 261-276
Open AccessIcaritin Improves the Hematopoiesis-Supportive Function of MSCs via A PRDX1–MAPK Axis After Chemotherapy